Suppr超能文献

相似文献

1
ACS chemical neuroscience molecule spotlight on Qnexa.
ACS Chem Neurosci. 2011 Apr 20;2(4):183-4. doi: 10.1021/cn200023v.
2
Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease.
Expert Rev Cardiovasc Ther. 2010 Dec;8(12):1777-801. doi: 10.1586/erc.10.125. Epub 2010 Aug 16.
3
Fixed-dose combination of phentermine-topiramate for the treatment of obesity.
Expert Rev Clin Pharmacol. 2013 May;6(3):235-41. doi: 10.1586/ecp.13.13.
4
Formulary management of 2 new agents: lorcaserin and phentermine/topiramate for weight loss.
J Manag Care Pharm. 2013 Oct;19(8):642-54. doi: 10.18553/jmcp.2013.19.8.642.
5
ACS chemical neuroscience molecule spotlight on contrave.
ACS Chem Neurosci. 2011 Sep 21;2(9):484-6. doi: 10.1021/cn200076y.
6
A review of the metabolic effects of controlled-release Phentermine/Topiramate.
Hormones (Athens). 2013 Oct-Dec;12(4):507-16. doi: 10.14310/horm.2002.1438.
7
Phentermine/topiramate for weight reduction and treatment of adverse metabolic consequences in obesity.
Drugs Today (Barc). 2011 Dec;47(12):903-14. doi: 10.1358/dot.2011.47.12.1718738.
9
New medications for weight loss.
JAAPA. 2012 Dec;25(12):59-60. doi: 10.1097/01720610-201212000-00013.
10
New antiobesity agents: lorcaserin (Belviq) and phentermine/topiramate ER (Qsymia).
Cardiol Rev. 2014 Jan-Feb;22(1):43-50. doi: 10.1097/CRD.0000000000000001.

引用本文的文献

1
Phentermine and topiramate for the management of obesity: a review.
Drug Des Devel Ther. 2011 Apr 5;7:267-78. doi: 10.2147/DDDT.S31443. Print 2013.

本文引用的文献

1
Prevalence and trends in obesity among US adults, 1999-2008.
JAMA. 2010 Jan 20;303(3):235-41. doi: 10.1001/jama.2009.2014. Epub 2010 Jan 13.
2
Appetite suppressants, cardiac valve disease and combination pharmacotherapy.
Am J Ther. 2009 Jul-Aug;16(4):354-64. doi: 10.1097/MJT.0b013e31817fde95.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验